What one share of BioXcel Therapeutics holds
BioXcel Therapeutics, Inc. (Nasdaq: BTAI, “the Company”) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology.
BioXcel Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.03 |
|---|---|
| Profit | −$3.16 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.27 |
| Cash and investments | $0.41 |
| Debt | $3.34 |
| Book value | −$3.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$7.50 | — | — | — | −$1.59 |
| 2018 | — | −$21.16 | $0.37 | −$15.21 | — | $39.73 |
| 2019 | — | −$32.38 | $0.85 | −$27.47 | — | $23.79 |
| 2020 | — | −$60.63 | $0.23 | −$49.19 | — | $135.44 |
| 2021 | — | −$64.87 | $0.27 | −$50.11 | — | $126.76 |
| 2022 | $0.21 | −$94.67 | $0.08 | −$77.38 | — | $43.64 |
| 2023 | $0.76 | −$98.33 | $0.01 | −$85.13 | — | −$30.20 |
| 2024 | $0.89 | −$23.51 | $0.00 | −$28.41 | — | −$30.01 |
| 2025 | $0.05 | −$5.73 | $0.00 | −$4.72 | — | −$4.28 |
Common questions about BioXcel Therapeutics
How much does one share of BioXcel Therapeutics earn?
Over the last 12 months, BioXcel Therapeutics lost $3.16 for each share on $0.03 of sales.
Does BioXcel Therapeutics pay a dividend?
BioXcel Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is BioXcel Therapeutics’s book value per share?
BioXcel Therapeutics’s book value is negative (−$3.69 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of BioXcel Therapeutics have?
Each share of BioXcel Therapeutics has $0.41 of cash and investments and $3.34 of debt, as of June 30, 2026.
What is BioXcel Therapeutics’s free cash flow per share?
−$2.27 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has BioXcel Therapeutics bought back shares?
BioXcel Therapeutics’s share count rose about 1917% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.